Study Participant and Tumor Characteristics
| Characteristic | Data |
| Age range (y) | 32–79 (median, 55) |
| Female (n) | 28 (28/28 = 100%) |
| Race (n) | |
| Caucasian | 17 (17/28 = 61%) |
| Black | 9 (9/28 = 32%) |
| Asian | 1 (1/28 = 4%) |
| Hispanic | 1 (1/28 = 4%) |
| Histology (n) | |
| IDC | 21 (21/29 = 72%) |
| ILC | 4 (4/29 = 14%) |
| Mixed (IDC and ILC) | 4 (4/29 = 14%) |
| Histologic grade (n) | |
| 1 | 2 (2/29 = 7%) |
| 2 | 15 (15/29 = 52%) |
| 3 | 11 (11/29 = 38%) |
| Not graded | 1 (1/29 = 3%) |
| AJCC tumor anatomic stage group* (n) | |
| 1A | 9 (9/29 = 31%) |
| 2A | 9 (9/29 = 31%) |
| 2B | 7 (7/29 = 25%) |
| 3A | 2 (2/29 = 7%) |
| 3B | 1 (1/29 = 4%) |
| IV | 1 (1/29 = 4%) |
| Receptor status (n) | |
| ER+ or PR+/HER2− | 20 (20/29 = 69%) |
| HER2+ | 5 (5/29 = 17%) |
| Triple-negative (ER−/PR−/HER2−) | 4 (4/29 = 14%) |
↵* According to AJCC Cancer Staging Manual, 8th ed.
AJCC = American Joint Committee on Cancer; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2.